SAN DIEGO, Jan. 10, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of clinically
actionable liquid biopsy tests designed to improve the outcomes of
cancer patients, announces that it has secured an in-network
provider agreement with Blue Cross Blue Shield of Texas (BCBSTX), the largest provider of health
benefits in that state.
"Determining the molecular status of a tumor can help physicians
individualize treatment for their patients and our highly sensitive
Target Selector™ platform can provide this important information
from a simple blood sample," said Biocept's Senior Vice President
and Senior Medical Director Veena
Singh, MD. "Our liquid biopsy testing is changing the way
physicians evaluate tumor status and monitor both response and
resistance to treatment."
"It is gratifying that health plans are seeing the value of our
liquid biopsy approach for profiling and monitoring important
cancer biomarkers," said Michael
Nall, President and Chief Executive Officer of Biocept.
"Partnering with health insurers is a major focus of our business
strategy, as it may increase physician access to this non-invasive
technology for their patients and provide timely adjudication of
claims for patients. Securing this in-network agreement is an
important milestone for Biocept, as Texas is one of our largest markets and BCBSTX
is the largest provider in that state. With this agreement, the
number of patients with in-network access to our tests has grown to
approximately 185 million, with some members having access via
multiple plans."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the
platform has demonstrated the ability to identify cancer mutations
and alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
diagnosis and treatment of cancer, our ability to increase
physician access to our technology, and our ability to provide
timely adjudication of claims, such statements are forward-looking,
and are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risk factors as set forth
in our Securities and Exchange Commission (SEC) filings. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocept-secures-in-network-provider-agreement-with-blue-cross-blue-shield-of-texas-300388558.html
SOURCE Biocept, Inc.